Xtl Biopharmaceuticals Ltd (XTLB) — SEC Filings
Xtl Biopharmaceuticals Ltd (XTLB) — 26 SEC filings. Latest: 6-K (Apr 29, 2026). Includes 24 6-K, 2 20-F.
View Xtl Biopharmaceuticals Ltd on SEC EDGAR
Overview
Xtl Biopharmaceuticals Ltd (XTLB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 29, 2026: XTL Biopharmaceuticals Ltd. filed a Form 6-K on April 29, 2026, reporting a Share Purchase Agreement. The filing includes a press release detailing this agreement, which is a significant event for the company. The specific terms and parties involved in the Share Purchase Agreement are not detailed i
Sentiment Summary
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 22 neutral, 2 mixed. The dominant filing sentiment for Xtl Biopharmaceuticals Ltd is neutral.
Filing Type Overview
Xtl Biopharmaceuticals Ltd (XTLB) has filed 24 6-K, 2 20-F with the SEC between Mar 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (26)
Risk Profile
Risk Assessment: Of XTLB's 26 recent filings, 0 were flagged as high-risk, 17 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Tal Klinger
- Roee Klinger
- Itay Weinstein
- Niv Segal
- Doron Turjeman
- Noam Band
- Shlomo Shalev
- Shareholders
Industry Context
XTL Biopharmaceuticals operates within the pharmaceutical preparations industry, focusing on the development and commercialization of biopharmaceutical products.
Top Tags
shareholder-meeting (6) · corporate-governance (6) · subsidiary (5) · management-change (4) · acquisition (4) · financial-results (3) · settlement (3) · ai (3) · data-extraction (3) · strategic-pivot (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| 6-K Document Size | 25258 | Size of the primary 6-K filing document. |
| EX-99.1 Document Size | 219582 | Size of the Share Purchase Agreement exhibit. |
| EX-99.2 Document Size | 23801 | Size of the Press Release exhibit. |
| Six Months Ended June 30, 2024 | H1 2024 | Period for which financial results were announced |
| American Depositary Shares outstanding | 2,923,276 | As of December 31, 2023 |
| Ordinary Shares outstanding | 544,906,149 | As of December 31, 2023 |
| Fiscal Year End | 2023-12-31 | Period covered by the report |
| Filing Date | 2024-04-30 | Date the report was filed |
| Minimum Bid Price | $1.00 | The threshold XTL Biopharmaceuticals needed to meet to regain compliance with Nasdaq listing rules. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Xtl Biopharmaceuticals Ltd (XTLB)?
Xtl Biopharmaceuticals Ltd has 26 recent SEC filings from Mar 2024 to Apr 2026, including 24 6-K, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of XTLB filings?
Across 26 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 22 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Xtl Biopharmaceuticals Ltd SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Xtl Biopharmaceuticals Ltd (XTLB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Xtl Biopharmaceuticals Ltd?
Financial highlights for Xtl Biopharmaceuticals Ltd are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for XTLB?
The investment thesis for XTLB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Xtl Biopharmaceuticals Ltd?
Key executives identified across Xtl Biopharmaceuticals Ltd's filings include Tal Klinger, Roee Klinger, Itay Weinstein, Niv Segal, Doron Turjeman and 3 others.
What are the main risk factors for Xtl Biopharmaceuticals Ltd stock?
Of XTLB's 26 assessed filings, 0 were flagged high-risk, 17 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Xtl Biopharmaceuticals Ltd?
Forward guidance and predictions for Xtl Biopharmaceuticals Ltd are extracted from SEC filings as they are enriched.